Summary
Marked prolongation of the QT interval may be associated with life-threatening ventricular tachycardia. The ventricular tachycardia has a polymorphous appearance and is usually induced by antiarrhythmic drugs. This peculiar type of ventricular tachycardia was termed by Desserstennetorsades de pointes because of its twisting ORS axis. The main reason to give this entity a special name that differentiates it from other types of ventricular tachycardia is the unique therapeutic approach to its treatment. Torsades de pointes can be suppressed by interventions that shorten the QT interval by increasing the heart rate, such as ventricular or atrial pacing, isoproterenol infusion, or atropine. Recently intravenous magnesium was also shown to be extremely effective. If torsades de pointes is treated as a conventional ventricular tachycardia by drugs that may further prolong the QT interval, it may lead to fatal results. To draw the attention of physicians to this unusual form of ventricular tachycardia, we suggest that the term torsades de pointes be kept. This specific diagnosis will hopefully guide the treating physician in selecting the appropriate mode of therapy.
Similar content being viewed by others
References
Selzer A, Wray HW. Quinidine syncope: Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias.Circulation 1964;30:17–26.
Dessertenne F. La tachycardie ventriculaire a deux foyers opposes veriables.Arch Mal Coeur 1966;59:263–272. (For English translation, seeCardiovasc Drugs Therap 1990;4: 1171–1176.)
Krikler DM, Curry PVL. Torsades de pointes, an atypical ventricular tachycardia.Br Heart J 1976;38:117–120.
Sclarovsky S, Strasberg B, Lewin RF, Agmon J. Polymorphous ventricular tachycardia: Clinical features and treatment.Am J Cardiol 1979;44:339–344.
Keren A, Tzivoni D, Gavish A, et al. Etiology, warning signs and therapy of torsades de pointes: A study of 10 patients.Circulation 1981;64:1167–1174.
Tzivoni D, Keren A, Stern S, Gottlieb S. Atypical ventricular tachycardia induced bv disopyramide.Arch Intern Med 1981;141:946–947.
Strasberg B, Sclarovsky S, Edberg A, et al. Procainamide induced polymorphous ventricular tachycardia.Am J Cardiol 1981;47:1309–1314.
Horowitz LN, Greenspan AM, Spielman SR, Josephson ME. Torsades de pointes: Electrophysiological studies in patients without transient pharmacologic or metabolic abnormalities.Circulation 1981;63:1120–1128.
Garan H, Fallon JT, Ruskin JN. Nonsustained polymorphic ventricular tachycardia induced by electrical stimulation in 3 week old canine myocardial infarction.Am J Cardiol 1981;48:280–286.
Anderson JL, Mason JW. Successful treatment by overdrive pacing of recurrent quinidine syncope due to ventricular tachycardia.Am J Med 1978;64:715–718.
Keren A, Tzivoni D, Golhman JM, et al. Ventricular pacing in atypical ventricular tachycardia.J Electrocardiol 1981; 14:201–206.
Tzivoni D, Keren A, Cohen AM, et al. Magnesium therapy for torsades de pointes.Am J Cardiol 1984;53:528–530.
Tzivoni D, Banai S, Schuger C, et al. Treatment of torsades de pointes with magnesium sulfate.Circulation 1988;77: 392–397.
Bailie DS, Inoue H, Kaseda S, et al. Magnesium suppression of early afterdepolarizations and ventricular tachyarrhythmias induced by cesium in dogs.Circulation 1988;77: 1395–1402.
Davidenko JM, Cohen L, Gooddrow R, Antzelevitch C. Quinidine induced action potential prolongation, early after-depolarization, and triggered activity in canine Purkinje fibers. Effects of stimulation rate, potassium and magnesium.Circulation 1989;79:674–686.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tzivonir, D., Keren, A., Banai, S. et al. Terminology of torsades de pointes. Cardiovasc Drug Ther 5, 505–507 (1991). https://doi.org/10.1007/BF03029777
Issue Date:
DOI: https://doi.org/10.1007/BF03029777